VistaGen Therapeutics, Inc.
(NASDAQ : VTGN)

( )
VTGN PreMarket: $ () as of AM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Bitcoin & Crypto Movers
Receive our Bitcoin / Cryptocurrency Reports, Free.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
CELGCelgene Corporation
1.80%108.001.1%$623.63m
GILDGilead Sciences, Inc.
2.24%75.880.9%$553.53m
AMGNAmgen Inc.
0.81%176.831.1%$472.09m
REGNRegeneron Pharmaceuticals, Inc.
0.14%381.322.7%$367.77m
BIIBBiogen Inc.
0.69%328.031.2%$319.81m
ALXNAlexion Pharmaceuticals, Inc.
-2.24%111.901.9%$254.48m
NKTRNektar Therapeutics
2.30%55.216.1%$211.68m
VRTXVertex Pharmaceuticals Incorporated
-1.34%141.681.9%$185.36m
ALNYAlnylam Pharmaceuticals, Inc
-2.06%128.2010.0%$179.97m
BLUEBluebird Bio, Inc.
17.91%201.8017.2%$170.21m
ILMNIllumina, Inc.
-1.63%214.113.5%$161.51m
AAgilent Technologies, Inc.
-0.65%66.941.5%$153.46m
INCYIncyte Corporation
0.69%97.252.5%$138.55m
BMRNBioMarin Pharmaceutical Inc.
7.46%88.114.4%$100.29m
JUNOJuno Therapeutics, Inc.
-14.34%50.2413.5%$94.10m

Company Profile

VistaGen Therapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to developing and commercializing innovative product candidates for patients with diseases and disorders involving the central nervous system. Its product candidate, AV-101, is a next generation, orally available prodrug candidate in Phase 2 development, initially for the adjunctive treatment of Major Depressive Disorder in patients with an inadequate response to standard antidepressants. The company was founded by H. Ralph Snodgrass and Gordon Keller on May 26, 1998 and is headquartered in South San Francisco, CA.